SCHEDULE: Janus Henderson Group PLC Amends Avidity Biosciences Stake
Beneficial Ownership Report (Amendment)
Janus Henderson Group plc has filed an Amendment No. 4 to Schedule 13G, reporting a 5.5% beneficial ownership stake in Avidity Biosciences, Inc.
Summary
- Janus Henderson Group plc, a Jersey-based entity, filed an Amendment No. 4 to Schedule 13G regarding its ownership in Avidity Biosciences, Inc.
- The filing indicates beneficial ownership of 8,224,930 shares of Common Stock in Avidity Biosciences, Inc.
- This aggregate amount represents 5.5% of the class of securities.
- Janus Henderson Group plc holds shared voting power and shared dispositive power over all 8,224,930 shares.
- The event requiring this statement occurred on November 28, 2025.
- The filing was made under Rule 13d-1(b), signifying an institutional investor holding shares in the ordinary course of business without the intent to influence control.
- Indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML are registered investment advisers furnishing investment advice to Managed Portfolios.
Sentiment
Score: 5
Explanation: Neutral. A Schedule 13G is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the issuer's performance, though a significant institutional stake can be seen as a vote of confidence.
Positives
- Janus Henderson Group plc maintains a significant stake (5.5%) in Avidity Biosciences, Inc., indicating continued institutional interest in the company.
Future Outlook
Not applicable as this filing is an ownership disclosure and does not contain forward-looking statements or guidance from the issuer.
Industry Context
This filing reflects an institutional investment manager's updated stake in a biotechnology company. Such filings are routine disclosures of significant ownership positions by large asset managers, indicating their portfolio allocations within the healthcare and biotech sectors.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Janus Henderson Group plc granted a Power of Attorney to Kristin Mariani and Caroline Barotti to execute and file documents related to ownership reporting requirements, including Forms 13D, 13F, 13G, and 13H. | 2022-12-09 | Streamlines the process for compliance with ownership reporting regulations for Janus Henderson Group plc. |
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
- Management: Awareness of a large institutional holder may influence strategic decisions, though this filing explicitly states the shares were not acquired to influence control.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date of execution of Power of Attorney by Janus Henderson Group plc. |
| 2025-11-28 | Date of event which requires filing of this statement. |
| 2025-12-05 | Date of signature on the Schedule 13G by Kristin Mariani. |
Keywords
Avidity Biosciences, Janus Henderson Group, Schedule 13G, Institutional Ownership, Common Stock, Biotechnology, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.